NCT01935167View on ClinicalTrials.gov

To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

February 28, 2015

Conditions
Diabetic Nephropathy
Interventions
DRUG

DW1029M 600mg

DW1029M 150mg 2 tablets b.i.d

DRUG

DW1029M 1200mg

DW1029M 300mg 2 tablets b.i.d

DRUG

Placebo

Placebo 2 tablets b.i.d.

Trial Locations (1)

100-130

DongWha Pharm, Seoul

Sponsors
All Listed Sponsors
lead

Dong Wha Pharmaceutical Co. Ltd.

INDUSTRY

NCT01935167 - To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy | Biotech Hunter | Biotech Hunter